Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

B Cell Activation and Differentiation

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...

Cells of the Adaptive Immune Response

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Secreted IgM deficiency alters the retinal landscape enhancing neurodegeneration associated with aging.

Immunity & ageing : I & A·2025

Same author

Complete primer set for amplification and expression of full-length recombinant human monoclonal antibodies from single human B cells.

Journal of immunological methods·2025

Same author

American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary.

Blood advances·2024

Same author

Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach.

Open forum infectious diseases·2024

Same author

An optimized filter trap assay for detecting recombinant authentic tau fibrils.

Free neuropathology·2024

Same author

A novel approach to Parkinson's disease treatment with a potentially dual-acting therapeutic agent that targets α-synuclein aggregation and neuron death.

Neural regeneration research·2024

Search research articles

Related Experiment Video

Updated: May 11, 2026

Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production

Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production

Published on: May 31, 2020

Human B-1 cells take the stage.

Thomas L Rothstein¹, Daniel O Griffin, Nichol E Holodick

¹Center for Oncology and Cell Biology, The Feinstein Institute for Medical Research, Manhasset, NY, USA. tr@nshs.edu

Annals of the New York Academy of Sciences

|May 23, 2013

Summary

This summary is machine-generated.

Human B-1 cells, crucial for immunity and debris removal, were identified by their unique CD20(+)CD27(+)CD43(+)CD70(-) markers. These cells offer potential for disease treatment and immune modulation.

More Related Videos

Genome Engineering of Primary Human B Cells Using CRISPR/Cas9

Genome Engineering of Primary Human B Cells Using CRISPR/Cas9

Published on: November 3, 2020

Related Experiment Videos

Last Updated: May 11, 2026

Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production

Retroviral Overexpression of CXCR4 on Murine B-1a Cells and Adoptive Transfer for Targeted B-1a Cell Migration to the Bone Marrow and IgM Production

Published on: May 31, 2020

Genome Engineering of Primary Human B Cells Using CRISPR/Cas9

Genome Engineering of Primary Human B Cells Using CRISPR/Cas9

Published on: November 3, 2020

Area of Science:

Immunology
Cell Biology

Background:

B-1 cells are vital for innate immunity and tissue homeostasis.
B-1 cells differ functionally and phenotypically from conventional B-2 cells.
Human B-1 cell identity was historically unclear compared to murine models.

Purpose of the Study:

To establish functional criteria for human B-1 cells.
To identify the distinct phenotypic profile of human B-1 cells.
To explore the potential roles and therapeutic applications of human B-1 cells.

Main Methods:

Established functional criteria based on murine B-1 cell characteristics.
Utilized reverse engineering to determine the human B-1 cell phenotype.
Analyzed B-1 cell populations in human umbilical cord and adult peripheral blood.

Main Results:

Identified the human B-1 cell phenotype as CD20(+)CD27(+)CD43(+)CD70(-).
Confirmed the presence of these cells in both cord and adult peripheral blood.
Highlighted the potential involvement of human B-1 cells in autoimmune diseases and T cell modulation.

Conclusions:

Human B-1 cells are now phenotypically defined, enabling further research.
These cells may contribute to disease pathogenesis and could be therapeutic targets.
Human B-1 cells represent a potential source for novel antibody therapies, particularly for age-related immune deficiencies.